ArticleInternational urology and nephrology2026
Metastatic non-muscle invasive bladder cancer: histology-specific metastatic patterns and survival in a national cancer database analysis.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastasis development in bladder cancer patients without any evidence of muscle invasion is known as metastatic non-muscle invasive bladder cancer (mNMIBC). Given its recent recognition, this condition is largely underexplored. The objective of our study was to analyze the baseline characteristics, metastatic patterns, and survival outcomes of this condition based on different histology subtypes.
methodsData from patients with mNMIBC were analyzed across different histology subtypes. Demographic and clinical variables were compared using Chi-square and Fisher's exact analysis. Kaplan-Meier analysis was performed to compare survival outcomes between the various types of histology.
resultsAmong the 537,674 patients diagnosed with NMIBC, 3982 had distant metastasis. The most common histopathology type was urothelial carcinoma [UC] (86.2%), followed by small cell carcinoma [SCC] (3.2%), squamous cell carcinoma [SqCC] (2.6%), adenocarcinoma (1.6%), and other variants (6.4%). The median overall survival (OS) of mNMIBC was 6.54 months. Among the various histopathology types, adenocarcinoma had the best OS (median OS: 12.71 months), followed by SCC (median OS: 8.87 months), UC (median OS: 6.83 months), and SqCC (median OS: 3.48 months). All results were statistically significant (p = 0.002). The common sites of metastasis were bone in UC (15.8%), lungs in SqCC (18.1%) and adenocarcinoma (16.9%), and liver in SCC (22%).
conclusionmNMIBC is an uncommon (0.74% of NMIBC) condition with a poor prognosis. The most common and least common subtypes were urothelial carcinoma and adenocarcinoma, respectively. In comparison with the other subtypes, adenocarcinoma had the best prognosis, and squamous cell carcinoma had the worst prognosis.
Indexed as
Identifiers
41219575What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.